Since its inception, Gynuity viewed mifepristone abortion as a revolutionary technology with the potential to increase autonomy and choice in the reproductive realm. Our aim has been to contribute to its availability in every way. Here we reflect on our work during the last two decades of increasing access to medical abortion (MA).

Advances since mifepristone approval in the U.S.
Two decades of research, action and impact

Since its inception, Gynuity viewed mifepristone abortion as a revolutionary technology with the potential to increase autonomy and choice in the reproductive realm. Our aim has been to contribute to its availability in every way. Here we reflect on our work during the last two decades of increasing access to medical abortion (MA).

Mifepristone approved in the U.S. 2000

2003 Gynuity Health Projects was founded continuing and expanding on research started at The Population Council with the vision of a world in which each individual has access to safe and effective reproductive and maternal health care

Mifepristone added to WHO Essential Medicine List to be used in combination with misoprostol 2005

2008 Mifepristone approved in 43 countries

Gynuity research shows mifepristone and misoprostol together are more effective than misoprostol alone for second trimester abortion 2011

2014 Gynuity disseminates information on alternative indications for mife-miso including intrauterine fetal death
Learn more about Gynuity's approach and impact to advance access to medical abortion globally and in the U.S. Please consider a donation to help us continue our work to increase access to safe, evidence-based person-centered abortion care and improve health and well-being.

DONATE NOW